Alembic Pharmaceuticals Limited Total Assets
Alembic Pharmaceuticals Limited total assets. Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) holds total assets worth Rs83.97 Billion INR (≈ $908.10 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see APLLTD stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Alembic Pharmaceuticals Limited (2011–2025)
Total assets of Alembic Pharmaceuticals Limited from 2011 to 2025. This chart illustrates how Alembic Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See Alembic Pharmaceuticals Limited stock price for real-time trading data and today's change.
Alembic Pharmaceuticals Limited - Asset Composition Analysis
Alembic Pharmaceuticals Limited Total Assets Breakdown (March 2025)
Alembic Pharmaceuticals Limited total assets breakdown as of March 2025. Alembic Pharmaceuticals Limited's total assets of Rs83.97 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.2% |
| Accounts Receivable | Rs14.00 Billion | 18.0% |
| Inventory | Rs22.88 Billion | 29.4% |
| Property, Plant & Equipment | Rs33.61 Billion | 43.2% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Alembic Pharmaceuticals Limited to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alembic Pharmaceuticals Limited's current assets represent 52.6% of total assets in 2025, a decrease from 64.2% in 2011.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, up from 0.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 43.2% of total assets.
Alembic Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Alembic Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Alembic Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.73 | 2.52 |
| Quick Ratio | 0.66 | 0.81 | 1.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs16.19 Billion | Rs15.91 Billion | Rs15.39 Billion |
Alembic Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Alembic Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | Rs77.73 Billion |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Alembic Pharmaceuticals Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alembic Pharmaceuticals Limited's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alembic Pharmaceuticals Limited (2011–2025)
The table below shows the annual total assets of Alembic Pharmaceuticals Limited from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs77.73 Billion ≈ $840.61 Million |
+20.59% |
| 2024-03-31 | Rs64.46 Billion ≈ $697.07 Million |
+4.25% |
| 2023-03-31 | Rs61.83 Billion ≈ $668.65 Million |
-13.19% |
| 2022-03-31 | Rs71.22 Billion ≈ $770.22 Million |
+6.16% |
| 2021-03-31 | Rs67.09 Billion ≈ $725.55 Million |
+12.02% |
| 2020-03-31 | Rs59.89 Billion ≈ $647.69 Million |
+25.35% |
| 2019-03-31 | Rs47.78 Billion ≈ $516.70 Million |
+21.23% |
| 2018-03-31 | Rs39.41 Billion ≈ $426.21 Million |
+46.69% |
| 2017-03-31 | Rs26.87 Billion ≈ $290.55 Million |
+9.24% |
| 2016-03-31 | Rs24.59 Billion ≈ $265.97 Million |
+49.86% |
| 2015-03-31 | Rs16.41 Billion ≈ $177.49 Million |
+34.76% |
| 2014-03-31 | Rs12.18 Billion ≈ $131.70 Million |
+16.22% |
| 2013-03-31 | Rs10.48 Billion ≈ $113.32 Million |
-0.39% |
| 2012-03-31 | Rs10.52 Billion ≈ $113.76 Million |
+24.69% |
| 2011-03-31 | Rs8.44 Billion ≈ $91.24 Million |
-- |
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more